SAN DIEGO, March 12, 2015 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq:OTIC), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and disorders of the inner and middle ear, today announced it will report financial results for the fourth quarter and full year 2014 as well as provide a corporate update at 4:30 p.m. ET on March 18, 2015.
The live call may be accessed by dialing (866) 953-6857 (domestic) or (617) 399-3481 (international). A live webcast of the call will be available online on the investor relations section of Otonomy's website at www.otonomy.com and will be archived there for 30 days. A telephone replay of the call will be available by dialing (888) 286-8010 (domestic) or (617) 801-6888 (international) and entering the conference code 90772974.
Otonomy is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and disorders of the ear. Otonomy's proprietary technology provides sustained exposure of drugs to the middle and inner ear following a single intratympanic injection. Otonomy has three product candidates in development. AuriPro™ is an antibiotic that has completed Phase 3 clinical trials in pediatric patients with middle ear effusion at the time of tympanostomy tube placement surgery. A New Drug Application for AuriPro has been submitted to the FDA. OTO-104 is a steroid that is in the first of two pivotal clinical studies for the treatment of patients with Ménière's disease. OTO-311 is an NMDA receptor antagonist in development as a treatment for tinnitus. For additional information please visit www.otonomy.com.
CONTACT: Media Inquiries Canale Communications Heidi Chokeir, Ph.D. Vice President 619.849.5377 firstname.lastname@example.org Investor Inquiries Westwicke Partners Robert H. Uhl Managing Director 858.356.5932 email@example.com